Sorrento Therapeutics Inc
OTC:SRNE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Sorrento Therapeutics Inc
Revenue
Sorrento Therapeutics Inc
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Sorrento Therapeutics Inc
OTC:SRNE
|
Revenue
$64.3m
|
CAGR 3-Years
22%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
66%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$61.2B
|
CAGR 3-Years
2%
|
CAGR 5-Years
6%
|
CAGR 10-Years
10%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$29.4B
|
CAGR 3-Years
3%
|
CAGR 5-Years
4%
|
CAGR 10-Years
-1%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$36.8B
|
CAGR 3-Years
12%
|
CAGR 5-Years
8%
|
CAGR 10-Years
5%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$12B
|
CAGR 3-Years
10%
|
CAGR 5-Years
14%
|
CAGR 10-Years
28%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$14.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
13%
|
|
Sorrento Therapeutics Inc
Glance View
Sorrento Therapeutics, Inc. engages in the research, development and manufacture of biopharmaceutical products. The company is headquartered in San Diego, California and currently employs 799 full-time employees. The company went IPO on 2007-01-19. The firm's segments include Sorrento Therapeutics and Scilex. The Sorrento Therapeutics segment is organized around Immune-Oncology therapeutic area, leveraging its G-MAB antibody library and targeted delivery modalities to generate cancer therapeutics. The Scilex segment is largely organized around its non-opioid pain management operations. Sorrento's immuno-oncology platforms include key assets such as fully human antibodies (G-MAB library), immuno-cellular therapies (DAR-T), antibody-drug conjugates (ADCs), and oncolytic virus (Seprehvec). Sorrento is also developing antiviral therapies and vaccines against coronaviruses, including Abivertinib, COVI-AMG, COVISHIELD, COVI-MSC and COVIDROPS; and diagnostic test solutions, including COVITRACK and COVISTIX.
See Also
What is Sorrento Therapeutics Inc's Revenue?
Revenue
64.3m
USD
Based on the financial report for Jun 30, 2023, Sorrento Therapeutics Inc's Revenue amounts to 64.3m USD.
What is Sorrento Therapeutics Inc's Revenue growth rate?
Revenue CAGR 10Y
66%
Over the last year, the Revenue growth was 17%. The average annual Revenue growth rates for Sorrento Therapeutics Inc have been 22% over the past three years , -16% over the past five years , and 66% over the past ten years .
